Immunotherapies for advanced hepatocellular carcinoma

被引:11
|
作者
Sun, Li-Yang [1 ,2 ]
Zhang, Kang-Jun [1 ,2 ]
Xie, Ya-Ming [2 ]
Liu, Jun-Wei [2 ]
Xiao, Zun-Qiang [2 ]
机构
[1] Zhejiang Chinese Med Univ, Sch Clin Med 2, Hangzhou, Peoples R China
[2] Zhejiang Prov Peoples Hosp, Affiliated Peoples Hosp, Hangzhou Med Coll, Gen Surg,Canc Ctr,Dept Hepatobiliary & Pancreat Su, Hangzhou, Zhejiang, Peoples R China
关键词
hepatocellular carcinoma; immunotherapy; PD-1; PD-L1; CTLA-4; LIVER-CANCER; SORAFENIB; THERAPY; SAFETY; PEMBROLIZUMAB; ATEZOLIZUMAB; IPILIMUMAB; INHIBITORS; TOXICITY; BLOCKADE;
D O I
10.3389/fphar.2023.1138493
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Primary liver cancer is the second leading cause of tumor-related deaths in China, with hepatocellular carcinoma (HCC) accounting for 80%-90% of these. Since there is a lack of symptoms in the early stages of HCC, a large proportion of patients were identified with unresectable HCC when diagnosed. Due to the severe resistance to chemotherapy, patients with advanced HCC were traditionally treated with systematic therapy in the past decades, and the tyrosine kinase inhibitor (TKI) sorafenib has remained the only treatment option for advanced HCC since 2008. Immunotherapies, particularly immune checkpoint inhibitors (ICIs), have shown a strong anti-tumor effect and have been supported by several guidelines recently. ICIs, for example programmed cell death-1 (PD-1) inhibitors such as nivolumab and pembrolizumab, programmed cell death ligand 1 (PD-L1) inhibitors such as atezolizumab, and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors such as ipilimumab, the ICI-based combination with TKIs, and VEGF-neutralizing antibody or systematic or local anti-tumor therapies, are being further studied in clinical trials. However, immune-related adverse events (irAEs) including cutaneous toxicity, gastrointestinal toxicity, and hepatotoxicity may lead to the termination of ICI treatment or even threaten patients' lives. This review aims to summarize currently available immunotherapies and introduce the irAEs and their managements in order to provide references for clinical application and further research.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Immunotherapies for hepatocellular carcinoma
    Liu, Justin K. H.
    Irvine, Andrew F.
    Jones, Rebecca L.
    Samson, Adel
    [J]. CANCER MEDICINE, 2022, 11 (03): : 571 - 591
  • [2] Immunotherapies for hepatocellular carcinoma
    Josep M. Llovet
    Florian Castet
    Mathias Heikenwalder
    Mala K. Maini
    Vincenzo Mazzaferro
    David J. Pinato
    Eli Pikarsky
    Andrew X. Zhu
    Richard S. Finn
    [J]. Nature Reviews Clinical Oncology, 2022, 19 : 151 - 172
  • [3] Immunotherapies for hepatocellular carcinoma
    Llovet, Josep M.
    Castet, Florian
    Heikenwalder, Mathias
    Maini, Mala K.
    Mazzaferro, Vincenzo
    Pinato, David J.
    Pikarsky, Eli
    Zhu, Andrew X.
    Finn, Richard S.
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2022, 19 (03) : 151 - 172
  • [4] Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
    Josep M. Llovet
    Roser Pinyol
    Mark Yarchoan
    Amit G. Singal
    Thomas U. Marron
    Myron Schwartz
    Eli Pikarsky
    Masatoshi Kudo
    Richard S. Finn
    [J]. Nature Reviews Clinical Oncology, 2024, 21 : 294 - 311
  • [5] Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
    Llovet, Josep M.
    Pinyol, Roser
    Yarchoan, Mark
    Singal, Amit G.
    Marron, Thomas U.
    Schwartz, Myron
    Pikarsky, Eli
    Kudo, Masatoshi
    Finn, Richard S.
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2024, 21 (4) : 294 - 311
  • [6] The Changing Landscape of Systemic Treatment of Advanced Hepatocellular Carcinoma: New Targeted Agents and Immunotherapies
    Marquardt, Jens U.
    Saborowski, Anna
    Czauderna, Carolin
    Vogel, Arndt
    [J]. TARGETED ONCOLOGY, 2019, 14 (02) : 115 - 123
  • [7] The Changing Landscape of Systemic Treatment of Advanced Hepatocellular Carcinoma: New Targeted Agents and Immunotherapies
    Jens U. Marquardt
    Anna Saborowski
    Carolin Czauderna
    Arndt Vogel
    [J]. Targeted Oncology, 2019, 14 : 115 - 123
  • [8] The promise of adoptive cellular immunotherapies in hepatocellular carcinoma
    Hendrickson, Peter G.
    Olson, Michael
    Luetkens, Tim
    Weston, Siani
    Han, Tiffany
    Atanackovic, Djordje
    Fine, Gabriel C.
    [J]. ONCOIMMUNOLOGY, 2020, 9 (01):
  • [9] Hepatocellular Carcinoma Immune Landscape and the Potential of Immunotherapies
    Giraud, Julie
    Chalopin, Domitille
    Blanc, Jean-Frederic
    Saleh, Maya
    [J]. FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [10] Statin therapy: a potential adjuvant to immunotherapies in hepatocellular carcinoma
    Wang, Jiao
    Liu, Chengyu
    Hu, Ronghua
    Wu, Licheng
    Li, Chuanzhou
    [J]. FRONTIERS IN PHARMACOLOGY, 2024, 15